Allarity Therapeutics Inc (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company developing targeted cancer therapies using a proprietary companion diagnostic platform called DRP (Drug Response Predictor). The company has no commercial revenue as of its 10-K filed 2026-03-30, with operations funded through equity and convertible debt financings rather than product sales. Its lead asset, stenoparib, is a PARP inhibitor licensed from Eisai and is in an ongoing Phase 2 clinical trial for ovarian cancer patients who have received at least three prior lines of therapy. The DRP companion diagnostic is designed to identify patients most likely to respond to treatment, with the FDA having previously approved an Investigational Device Exemption (IDE) for the stenoparib-specific DRP test. Allarity owes Eisai milestone payments of up to $94 million and a $50 million sales milestone if annual stenoparib product sales reach $1 billion, plus royalties on annual incremental sales.

Revenue model

No product revenue has been generated as of the 10-K filed 2026-03-30. The income statement shows a License Revenue line with no disclosed amounts in the redacted filing. Operations are funded through preferred stock offerings, convertible notes, and private placement financings. The company is pre-commercial and reports net losses for both FY2025 and FY2024.

Products and services

Stenoparib: an oral PARP inhibitor licensed from Eisai, in Phase 2 clinical trials for heavily pre-treated ovarian cancer. DRP (Drug Response Predictor) companion diagnostic platform: a proprietary biomarker tool used to select patients with a DRP score above 50 (DRP+) for enrollment in stenoparib trials. The FDA granted an Investigational Device Exemption (IDE) for the stenoparib-specific DRP diagnostic.

Customers and end markets

End market is oncology, specifically ovarian cancer patients who have received at least three prior lines of therapy. No commercial customers as of the filing date. Clinical trial sites are located in the U.S. and Europe.

Value-chain role

Clinical-stage drug developer and biomarker diagnostics innovator. Allarity in-licenses drug candidates, conducts clinical development, and aims to commercialize therapies paired with its DRP companion diagnostic. Relies on contract research organizations (CROs), principal investigators, and third-party vendors for trial operations.

Geographic exposure

Clinical trial operations span the U.S. and Europe as of the 10-K filed 2026-03-30. The company references potential regulatory submissions to the FDA (U.S.), EMA (Europe), and MHLW (Japan) as future milestones under the Eisai License Agreement.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations Peers: Protagenic Therapeutics Inc Plus Therapeutics Inc CervoMed Inc Decoy Therapeutics Inc Canton Strategic Holdings Inc Lixte Biotechnology Holdings Inc Aixcrypto Holdings Inc ProtoKinetix Inc